International perspectives on LI-RADS
- PMID: 39699666
- DOI: 10.1007/s00261-024-04729-3
International perspectives on LI-RADS
Abstract
Given the crucial role of imaging in HCC diagnosis, LI-RADS CT/MRI was developed to standardize the imaging interpretation and reporting of HCC in patients at risk for HCC and categorize hepatic observations on an ordinal scale according to the likelihood of HCC. LI-RADS has since been expanded to include 5 algorithms: LI-RADS US Surveillance, contrast-enhanced US (CEUS) LI-RADS, LI-RADS CT/MRI, and LI-RADS Treatment Response Assessment. LI-RADS has been adopted broadly in North America, however with less ubiquitous adoption outside of North America. Further elucidation of the perceived strengths and weakness of the LI-RADS algorithm, as it pertains to various geographic regions, will continue to inform a future system that may be more readily adopted globally. Therefore, the aim of this article is to summarize HCC risk factors and imaging guidelines in select geographically disparate regions, and to solicit feedback from liver imaging experts on the limitations and barriers to adoption of LI-RADS algorithms in their patient populations.
Keywords: HCC; Hepatocellular carcinoma; LI-RADS; LI-RADS CT/MRI; LI-RADS International Working Group; LI-RADS US surveillance; LI-RADS treatment response.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
References
-
- Villanueva A. Hepatocellular Carcinoma. N Engl J Med 2019;380(15):1450–1462. doi: https://doi.org/10.1056/NEJMra1713263 - DOI - PubMed
-
- Valery PC, Laversanne M, Clark PJ, Petrick JL, McGlynn KA, Bray F. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology 2018;67(2):600–611. doi: https://doi.org/10.1002/hep.29498 - DOI - PubMed
-
- Allaire M, Bruix J, Korenjak M, Manes S, Maravic Z, Reeves H, Salem R, Sangro B, Sherman M. What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association. JHEP Rep 2022;4(12):100578. doi: https://doi.org/10.1016/j.jhepr.2022.100578 - DOI - PubMed - PMC
-
- Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7(1):6. doi: https://doi.org/10.1038/s41572-020-00240-3 - DOI - PubMed
-
- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2024;74(3):229–263. doi: https://doi.org/10.3322/caac.21834 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical